mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
India's strategy against Covid was more effective than any other countries in the world
The session took place in the presence of Union Ministers Hardeep Singh Puri and Gen V K Singh along with Anil Agarwal, Rajya Sabha Member of Parliament
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Urges everyone to follow COVID Appropriate Behaviour and curb any misinformation
To enable company to be future-ready by tapping potential in CDMO space
Subscribe To Our Newsletter & Stay Updated
